Marc Voigt, CEO and CEO of Immutep Limited (ASX:IMM), discusses the progress of the company’s drug IMP761, which is active in more than 90% of autoimmune diseases.
Peter Milios: My call is Peter Milios from Finance News Network and we’re speaking to Immutep (ASX: IMM). Immutep trades under the ASX ticker “IMM” and has a market capitalization of approximately $487 million. Immutep is a clinical- we place a biotechnology company at the forefront of the progression of novel LAG-3 immunotherapies for cancer and autoimmune diseases. He joins us through CEO Marc Voigt. Marc, welcome back to the network.
Marc Voigt: Thank you, Peter.
Peter Milios: Marc, let’s start by talking about your most recent announcement: the first dosed topic in the Phase I study of IMP761. How important is this news?
Marc Voigt: It is very significant because it marks the end of the so-called preclinical progression of this program. Before you can apply the product and apply it to a human, you have to check it for a long time. So for a few years you have to do it with the right quality. And now we have begun the so-called examination of the first human beings. Thus, in the coming months up to 49 participants will be treated.
Peter Milios: What are the advantages of the first subject being dosed through the Human Medicines Research Centre?
Marc Voigt: We have started a vital collaboration because it is a centre of excellence. Typically, one phase I look at focuses on security. Of course, this is also the case here. However, this center has developed rapid tests that already allow us to know the biological activity of the drug. We are talking about the picture of autoimmune diseases, and in the last part of a trial healthy volunteers will be challenged. we cause a planned inflammation of the skin and then we administer a placebo or IMP761 (that’s what our drug is called) and we see the difference or we analyze the pharmacokinetic and pharmacodynamic effects, we analyze the safety. Therefore, for a Phase I, a very complicated setup. This is a double-blind, placebo-controlled phase I involving a total of 49 participants. Therefore, it is specialized training aimed at obtaining as much data imaginable about this phase I clinical trial.
Peter Milios: And Marc, what are the steps for IMP761?
First of all, we’re going to do this clinical trial and hopefully we’ll get a very, very smart protection profile, it’s an increasing dose, as you would usually, and then we’ll read the biological activity. And beyond that, for an imaginable Phase II clinical trial, a selection would have to be made in terms of indication. This can be type 1 diabetes, rheumatoid arthritis or psoriasis, for example, because our treatment is potentially active in more than 90% of autoimmune diseases. It is a bottom-up approach; Which means that we are addressing the root cause of the disease, not a symptomatic treatment, but addressing the root cause of the disease. That is why it is relatively widely applicable and the clinical truth will have to show precisely where we deserve to take our first step and how we will expand this program in the future.
Peter Milios: And in the company as a whole, how are you progressing and what can we expect from the company over the next 6 to 12 months?
Marc Voigt: The company is really progressing very well. We will have a series of news for the remainder of this year, adding life milestones, more knowledge about head and neck cancer, more knowledge about soft tissue sarcoma. Above all, we will become a phase III company. So either through the end of this year or the first quarter of next year, we will welcome the first patient to a Phase III clinical trial in first-line mobile non-small lung cancer. This is the largest market in oncology. And we started, about 8 weeks ago, a collaboration with the American Merck, and we combined another drug called Eftilagimod with Keytruda, the best-selling logo in the entire industry, in the entire pharmaceutical industry, to meet the vital maximum. affairs. Marketplace, and this entire Marketplace is eligible for the so-called anti-PD-1 treatment. Therefore, our goal is to establish a new standard of care in the larger oncology market, something that has never been attempted by any Australian company. And we will make it happen in the coming months to start this clinical trial. And then in the early part of next year, we’ll look at data from IMP761, the study we just talked about. We will see the knowledge in our future clinical trials. We will enroll patients in the phase III clinical trial. Also – it shouldn’t – metastatic breast cancer. So there’s a lot going on. There is no shortage of milestones, catalysts and news sources, which is vital in our industry.
Peter Milios: Marc, thank you for your time today.
Marc Voigt: Peter, thank you very much. My pleasure.
Finish
Get updates delivered straight to your inbox.
Terms of Use | Privacy Policy | Contact | Announce
Increases across the board of Deep Leads’ resources: quality, tonnage and target area ABx Group has reported a 30% increase in its mineral resource estimate (MRE) at Deep Leads’ rare ion adsorption clay (IAC) earth deposit in northern Tasmania. The accumulation in MRE comes from 36 tested outlets, representing a significant northward extension for the existing Deep Leads prospect.
Lake Resources (LKE. ASX) – LKE has signed two non-binding MoUs in the 10-day area. Ford Company (Ford) signed a memorandum of understanding for around 25,000 t/year and last week, Hanwa, a Japanese raw materials trader, signed a memorandum of understanding for up to 25,000 t/year. Subject to execution, this is a feat as Ford and Hanwa are set to engage in longer-term strategic partnerships with LKE. Commercial negotiations are still ongoing but should, if Ford and Hanwa inject new capital into LKE, further de-risk the project financing and thus ensure that LKE and Kachi are fully funded.
Two recent gravity studies have particularly exceeded expectations and revealed prospects for extension of the existing MRE at Throssell Lake, as well as a significant expansion opportunity at Yeo Lake. This reinforces the prospect of a multi-decade Tier 1 SOP production center around Lake Throssell.
Lately, TMG is completing paintings in preparation for the PFS planned for early 2023, adding the start of drilling in Q3 2022, evaporation testing and permitting activities. The effects of these systems will affect the PFS and any long-term resource improvements.
SOP reference prices have increased to around $940/t due to recent geopolitical developments. The October 2021 scoping study assumed an SOP value of $550/t and contained a sensitivity study showing that each 10% accrual in value effects amounted to $144 million accrued to the NPV of the $364 million allocation. The accrual of around 70% compared to the scoping study implies an NPV of the allocation of approximately $1. 4 billion.
Despite the fall in oil and fuel prices, which fell by 5. 4% and 19. 7% respectively in August, Calima managed to show an improvement in its main indicators.
WT Financial Group Limited (WTL) is a diversified money company in development, founded in 2010 and indexed to the Australia Securities Exchange (ASX) in 2015. Their recommendations and product offerings are primarily provided through an organization of independent money advisors who act as legal representatives. of WTL under its broker organization businesses Wealth Today Pty Ltd (Wealth Today) and Sentry Group Pty Ltd (Sentry Group). He has approximately 275 advisers at over two hundred money advisory firms across Australia. It also operates a direct-to-consumer operation under its Spring Financial Group brand.
In May 2021, Corporate Connect analyst Marc Sinatra published a comprehensive research report on ASX-listed biotech Immutep Ltd (ASX: IMM). It became so inspired by IMM that Corporate Connect considered it imperative to publish a follow-up report valuing the company, as The market did not see the great prospects for eftilagimod alfa (efti).
This follow-up report was released today. Using comparables, after adding a reduction of money to its EV estimate and dividing by the total number of percentages issued, Corporate Connect now puts the fair price of a percentage of Immutep at AU$2. 20.